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Abstract
Epigenetic treatment has been approved by regulatory agencies for haematological malignancies. The success observed
in cutaneous lymphomas represents a proof of principle that similar results may be obtained in solid tumours. Several
agents that interfere with DNA methylation-demethylation and histones acetylation/deacetylation have been studied,
and some (such as azacytidine, decitabine, valproic acid and vorinostat) are already in clinical use.
The aim of this review is to provide a brief overview of the molecular events underlying the antitumour effects of
epigenetic treatments and to summarise data available on clinical trials that tested the use of epigenetic agents
against solid tumours. We not only list results but also try to indicate how the proper evaluation of this treatment
might result in a better selection of effective agents and in a more rapid development.
We divided compounds in demethylating agents and HDAC inhibitors. For each class, we report the antitumour
activity and the toxic side effects. When available, we describe plasma pharmacokinetics and pharmacodynamic
evaluation in tumours and in surrogate tissues (generally white blood cells).
Epigenetic treatment is a reality in haematological malignancies and deserves adequate attention in solid tumours. A
careful consideration of available clinical data however is required for faster drug development and possibly
to re-evaluate some molecules that were perhaps discarded too early.
Keywords: Epigenetic treatment, Histone deacetylases (HDACs), Histone methyltransferases (HMTs), DNA methylation,
DNA-methyltransferases, ncRNAs, Azacytidine, Decitabine, Valproic acid, Suberoylanilide hydroxamic acid (SAHA)
Background
Research on tumour biology has provided conclusive
evidence on the primary role of genetic alterations in the
initiation and progression of cancer. However, the
deregulation of epigenetic processes such as DNA
methylation and alterations of “histone code” are equally
important oncogenic factors per se [1–4]. Epigenetic
processes affect the packaging of chromatin and direct
distinct cellular gene expression programmes. They are
heritable through cell division and do not involve
changes in the DNA sequence [4–6]. Operating at the
level of chromatin structure, epigenetic mechanisms play
a key role during embryogenesis, X-chromosome silencing,
cellular proliferation and differentiation and in disease
states [2, 4–6]. They also facilitate a selective readout of
the genome, thereby regulating stem cell developmental
potential and cell fate. Subtle disturbances of the epigenetic
framework in progenitor, differentiating or terminal cells
may, besides well-known genetic alterations, promote
carcinogenesis [7, 8]. The dynamic and reversible
nature of epigenetic mechanisms makes these processes
of therapeutic relevance in many diseases including
cancer.
Epigenetic processes involve methylation of DNA and
post-translational modification of nucleosomal histones,
which contribute to a complex “epigenetic code” that
superposes the nucleotide sequence to direct gene
expression [4, 9–11] (Fig. 1a).
DNA methylation results from the transfer of a methyl
group from a methyl donor substrate, namely S-adenosyl-
L-methionine (AdoMet), to the 5′ position of a cytosine
in a CpG context. CpG dinucleotides can be sparse or
tend to be gathered in repetitive sequences in or around
gene promoters in regions known as CpG islands. The
methylation status of CpG moieties within regulatory
DNA sequences affects the transcription of the related
gene [2, 10]. The creation of DNA methylation patterns
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during the embryogenesis establishes the compartmentali-
zation of genome into transcriptionally active and inactive
domains. DNA methylation is fundamental for a correct
expression of imprinted genes, chromosomal dosage
compensation (X-chromosome inactivation) and tissue-
specific gene expression [2, 3, 12–14].
The oncogenic effect of DNA methylation is mainly
related to the formation of a repressive chromatin struc-
ture on promoter regions that impairs the constitutive
expression of genes involved in cell cycle regulation,
DNA repair, apoptosis, differentiation, drug resistance,
angiogenesis and metastasis [1–4]. A family of enzymes
known as DNA methyltransferases (DNMTs) catalyses
the DNA methylation reaction. DNMT1 is a mainten-
ance methylase that recognises and methylates hemi-
methylated CpG dinucleotides during DNA replication
allowing the propagation and conservation of the DNA
methylation patterns through the future generations
[14, 15]. DNMT3a and 3b generally act as de novo
methylases. They are highly expressed in embryonic
stem cells, early embryos and developing germ cells
and, at a low rate, in somatic tissues or postnatal animals.
DNA methyltransferase-3-like (DNMT3-Like) lacks en-
zymatic activity but may be essential for the establishment
of maternal methylation imprints and the appropriate
expression of maternally imprinted genes. The inhibitory
effect of CpG island methylation on gene expression is
mediated by the involvement of proteins with high affinity
for methylated CpGs. These methyl CpG-binding proteins
(MeCP1, MeCP2, MBDs and Kaiso) [16–21] exert their
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Fig. 1 Schematic representation of gene expression regulation by epigenetic drugs, components of the DNA and chromatin-modifying
machinery and ncRNAs. a Epigenetic drugs reported to be effective against cancer cells inhibit the activity of DNA methyltransferases (DNMTi)
or histone deacetylases (HDACi). DNMTs add a methyl group (CH3) to the 5′ carbon atom of cytosine in DNA CpG dinucleotides. DNMTs also
participate in multiprotein chromatin-modifying complexes containing histone deacetylases (HDACs) and histone methyltransferases (HMTs),which induce
post-translational modifications of lysine residues in the amino terminal tails of nucleosomal histones, including deacetylation (HDACs), methylation (HMTs)
and acetylation (histone acetyltransferases (HAT). Specific molecular modifications on CpGs and nucleosomal histones affect the higher order of chromatin
architecture and function by changing the interaction of histones with DNA or the contact between different histones in adjacent nucleosomes. This allows
or denies the accessibility of the transcriptional machinery and DNA-binding proteins to specific sites on genome, resulting in activation or silencing of
gene transcription. Ac acetylation, Me methylation. b Short and long ncRNA are emerging as novel regulators of chromatin structure,
alternative to DNA-binding proteins. They can act as key specificity determinants for epigenetic regulation of gene expression. In the nucleus, both
short and long ncRNAs can bind complementary sequences on DNA or nascent RNA transcripts and guide the Argonaute-containing complexes
(Ago) to recruit HDACs, HMTs and DNMTs for gene silencing. Nascent lncRNAs can also be tethered to the locus from which they are transcribed
through association with RNA polymerase II (Pol II). In the cytosol, microRNAs and siRNAs act as post-transcriptional regulators of the expression of
HDAC and DNMTs through their complementarity with mRNA sequences
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function as transcriptional repressors via chromatin modi-
fication. Methyl CpG-binding proteins are often part of
large repressor complexes as NuRD, NoRC, mSin3A and
SWI-SNF. Repressor complexes recruit histone deacety-
lases (HDACs) and histone methyltransferases (HMTs) on
methylated target promoter sequences. These enzymes
catalyse covalent post-translational modifications of spe-
cific residues on histone 3 (H3) and 4 (H4) N-terminal
tails (e.g. deacetylation of lysine (K) 9, demethylation of
K4 and methylation of K9 and K27 of H3), inducing a
compacted transcriptionally inactive chromatin structure.
Histone acetylation status also depends on the contrasting
activities of HDACs and histone acetyltransferases (HAT)
group of enzymes. The latter are presumed to induce
histone tail modifications (e.g. acetylation of K9 and
K14 of H3), resulting in a transcriptionally active chro-
matin state. As for histone acetylation, histone lysine
methylation can be dynamically regulated by the recruit-
ment of members of the histone lysine methyltransferases
and demethylase class of enzymes, which impose memory
on gene transcription [22]. Other histone tail modifica-
tions include phosphorylation, sumoylation, ubiquitination
and ADP ribosylation. Overall, DNA methylation and his-
tone modifications work together to assemble a chromatin
structure, which dynamically shifts from a transcription-
ally permissive state to a transcriptionally inactive state
and vice versa [2, 14].
Inhibition of HDACs can be achieved in normal condi-
tions by endogenous molecules [23] explaining the
plausibility of this process in the normal regulation of
gene expression.
Aberrant DNA methylation and chromatin modifica-
tions, altering gene transcription states, are common hall-
marks of human tumour cells [24]. Studies on leukaemias
have provided paradigmatic examples for the functional
implications of genetic and epigenetic alterations in cancer
development [25, 26]. These studies underline the possi-
bility of reversing disease-associated aberrant epigenetic
states by targeting the catalytic activities of chromatin
remodelling enzymes. Thus, these enzymes are attractive
targets for therapeutic intervention in cancer [27–29].
The possibility of drug development in this field has re-
cently been reviewed [22, 24, 30, 31].
Evidence is growing that non-coding RNAs (ncRNAs)
are involved in inducing chromatin modifications and
act as additional molecular determinants for epigenetic
regulation of gene expression also in human cells [32–34]
(Fig. 1b). NcRNAs comprise a large and heterogeneous
family of RNA molecules differing in length (short,
such as microRNAs, and long ncRNAs), which are
transcribed from DNA but not translated into proteins.
By regulating gene expression at the transcriptional and
post-transcriptional level, they affect a broad range of
physiologic functions and pathologies such as neoplastic
diseases [35, 36]. Both short and long ncRNAs appear to
function by guiding the recruitment HDACs, HMTs and
DNMTs, and other proteins involved in the epigenetic
regulation of transcription, to homology-containing loci
on gene promoters and in the genome. Moreover, short
ncRNA, as microRNAs and siRNAs, can repress the
expression of HDAC, DNMTs and other components of
chromatin-modifying complexes at the post-transcriptional
level by interacting with their mRNAs [32, 33, 35] (Fig. 1b).
Therefore, ncRNAs play direct roles in DNA methylation,
heterochromatin formation, histone modification and gene
silencing. In turn, they are epigenetically targeted for
repression or activation; this can be a valuable way of amp-
lifying changes in the levels of downstream effectors.
Knowledge of these emerging regulatory roles of ncRNAs
has implication not only in cellular physiology and path-
ology but also for the development of novel epigenetic
drugs that re-establish the correct pattern of gene expres-
sion in complex diseases such as cancer.
Currently in the clinical setting, there are two classes
of epigenetic drugs, which act through the inhibition of
the enzymatic activities responsible for epigenetic tran-
scriptional silencing: DNMTs and HDACs (Fig. 2).
DNA methylation inhibitors 5-azacytidine (azacytidine)
and 5-aza-2′-deoxycytidine (decitabine) have been
approved by the US Food and Drug Administration
(FDA) in 2004 and 2006, respectively, for the treatment
of patients with myelodysplastic syndromes (MDS). US
FDA approved the HDAC inhibitors suberoylanilide
hydroxamic acid (SAHA, vorinostat, in 2006) and romi-
depsin (depsipeptide, in 2009) for the treatment of patients
with progressive, persistent or recurrent cutaneous T-cell
lymphoma [37]. In 2015, FDA approved panobinostat in
combination with bortezomib and dexamethasone for the
treatment of patients with multiple myeloma [38] and beli-
nostat for the treatment of patients with peripheral T-cell
lymphoma (PTCL) [39].
The success of epigenetic therapies in inducing clinical
responses in MDS and lymphoma not only gave to this
kind of treatment high visibility, but it also suggested
that similar results might be obtained in solid tumours
and that this line of research deserves proper evaluation.
The relevance of epigenetic treatment in haematological
malignancies (leukaemias, lymphomas, myelodysplastic
syndromes, myeloma) have already been described in
detail [40].
In clinical studies, epigenetic treatment was administered
alone or in combination with standard anticancer therapies
(usually chemotherapy, sometimes radiotherapy) to im-
prove their antitumour activities [41]. In some cases, the
aim was more directly related to the control of gene activ-
ity and to prevent the development of resistance due to the
overexpression of a specific gene, for example thymidylate
synthase [42].
Nervi et al. Clinical Epigenetics  (2015) 7:127 Page 3 of 20
In several papers [43, 44], particularly those more re-
cently published [45, 46], a detailed explanation for the
combination of epigenetic and standard anticancer treat-
ment is provided together with complete and stimulating
results.
The present review will focus on the epigenetic treat-
ment of solid tumours: we collected data from clinical
studies available as full papers, data on ongoing studies
are available at clinicaltrials.gov site and have been
reviewed [47].
In the text, we discuss data on the pharmacology,
pharmacokinetics (PK) and pharmacodynamics (PD),
on the toxic side effects and on the antitumour activity
of epigenetic treatments. In the tables, we give more
details for epigenetic treatment alone (Table 1) or in
combination with traditional anticancer agents or
radiotherapy (Table 2).
Pharmacological aspects
An effective treatment, based on a sound scientific ration-
ale, requires the identification of the relevant target(s) and
the demonstration that the target(s) can be inhibited with-
out excessive toxicity, and that the duration of this effect
is sufficient to interfere with cell growth.
In the case of epigenetic treatment, it is necessary to
prove that one of the different mechanisms that finely
regulate gene expression (see above) is altered. Even if
this mechanism is well established for many molecules,
for some compounds such as CI-994 (N-acetyl-dinaline),
an inhibitor of class I HDACs, the actual relevance of an
epigenetic mode of action remains uncertain [27, 48, 49].
The list of epigenetic drugs is becoming longer every day
and it also includes “old” drugs: Hydralazine, for example,
has long been used as an anti-hypertensive agent, but it has
recently been recognised as a demethylating agent [50, 51].
HDAC inhibitors
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Fig. 2 Chemical structures of different classes of DNMT and HDAC inhibitors. Antimetabolites 5-azacytidine and decitabine (5-aza-2′-deoxycytidine) are
cytidine analogues; these nucleoside derivatives are incorporated into DNA leading to covalent adduct formation, thus acting as mechanistic inhibitors.
The non-nucleoside DNMT inhibitor hydralazine interacts within the binding pocket of the enzyme interfering with the DNA methylation mechanism
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Table 1 Studies on epigenetic treatment alone
Drug (s) and schedule Study type - histology (number of patients) Results and data provided Reference
Abexinostat (S78454/PCI-24781)
p.o. 60 mg/m2 bid 4 days on/3 days off
Mixed tumours (15 pts) PK/PD model predicts thrombocytopenia [90]
Azacytidine + Valproate
Aza s.c. for 10 days q. 28 days.
MTD 75 mg/m2/day
VPA in plasma 75–100 μg/ml (a)
Dose escalation
Mixed tumours (55 pts)
PBMC: DNA methylation decreased. H3
acetylation increased. Patients with stable
disease had more H3 acetylation.
DLT: neutropenic fever and thrombocytopenia
[68]
Azacytidine +Entinostat
Aza 30–40 mg/m2/day for days 1–6 and 8–10 q 28 days
Entinostat 7 mg/m2 days 3 and 10
Phase I/II trial
NSCLC (45 pts)
Demethylation of 4 epigenetically silenced genes
(CDK2a, CDH13, APC, RASSF1a). In plasma DNA
was associated with improved progression-free and
overall survival
[62]
Azacytidine (AC) Phenylbutyrate (PHB)
AC 10-25mg/m2/day for 21 days,
75 mg/m2/day for 7 days
PHB 200–400 mg/m2 days 6, 13 and 20
Phase I
Mixed tumours (27 pts)
Toxicity: neutropenia, anaemia. No PK interaction
“No conclusive statement can be made on histone
acetylation or methyltrasferase activity”.
[91]
Decitabine + VPA
Dec 5–15 mg/m2/day for 10 days.
VPA 10–20 mg/kg/day for days 5–21 q 28 days
Phase I
NSCLC (8 pts)
Neurological toxicity.
Increase in foetal Hb levels in all pts
[63]
Belinostat
1000 mg/m2/day i.v. for days 1–5 q 21 days
Phase II
Ovarian: platinum resistant (18 pts) or micropapillary (14 pts)
Toxicity: thrombosis (3 pts).
Increased H3 acetylation in PBMC and in two tumours
[73]
Belinostat
1000 mg/m2/day i.v. for days 1–5 q 21 days
Phase II
Refractory Thymic epithelial tumours (41 pts)
Nausea, vomiting, fatigue
Modest activity
Protein acetylation did not predict outcome
[92]
Belinostat
600–1400 mg/m2/day i.v. for days 1–5 q 3 weeks .
Phase I/II
Hepatocarcinoma (60 pts)
PK linear. MTD not reached at 1400 mg/m2.
Toxicity: abdominal pain, liver toxicity, vomiting.
Plasma concentrations higher than effective in vitro
levels for 4 hours.
Disease stabilisation. High HR23B associated with
more stabilisation.
[93]
Belinostat
1000 mg/m2/day i.v. for days 1–5 q 21 days
Mesothelioma (pre-treated) (13 pts) Not active in terms of RR
toxicitiy: nausea, emesis, fatigue and constipation.
One fatal cardiac arrhythmia
[94]
Belinostat, (oral formulation)
150–1000 mg/m2/day for days 1–5 q 21 days
Pharmacological evaluation
Mixed tumours (46 pts)
PK and PD: results similar to the parenteral formulation [95]
CHR-3996
5–160 mg/day p. o.
RD 40 mg/day p.o.
Phase I
Mixed tumours (39 pts)
DLT: thrombocytopenia, fatigue, atrial fibrillation, ECG
alterations, elevated creatinine.
AUC proportional to dose, plasma concentration sufficient
for preclinical antitumour activity
Effect on histone acetylation in PBMC
[45]
CI-994
2–8 mg/m2/day
RD 8 mg/m2/day for 8 weeks q 10 weeks
Phase I
Mixed tumours (53 pts)
Toxicity: Thrombocytopenia (DLT).
PK data.
[48]
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Table 1 Studies on epigenetic treatment alone (Continued)
MGCD0103
12.5-56 mg/m2/day p.o.
3 times/week for 2 weeks q 3 weeks
RD 45 mg/m2/day
Phase I
Mixed tumours
Inhibition of HDAC activity and induction of
acetylation of H3 histones in peripheral WBCs
[96]
MS-275
MTD 10 mg/m2 q14 days
Phase I
Mixed tumours (31 pts)
Toxicities: nausea, vomiting, anorexia, fatigue.
Half-life 39–80 hrs (longer than expected). Linear PK.
Increased H3 acetylation in PBMC. Peak plasma
levels higher than effective in vitro concentration.
[97]
Panobinostat
20 mg p.o. twice/week
Pharmacological study
Mixed tumours (36 pts)
No effect of food on PK parameters [98]
Panobinostat
40 mg p.o. three times/week
Sarcoma (47 pts)
Ovarian Sex Cord Tumours (5 pts)
Poorly tolerated. No activity in sarcoma. Activity in OSCT
Toxicity: thrombocytopenia, fatigue, anaemia
[99]
Panobinostat
20 mg/m2 for days 1 and 8 q 21 days
Prostate (35 pts) No clinical activity
Toxicity: fatigue, thrombocytopenia, nausea
[100]
Panobinostat
20 mg
Mixed tumours (4 pts) PK determined by trace radiolabelled 14C excretion
Rapid oral absorption, liver and renal excretion
[101]
Pivanex
2.34 g/m2/day in 6 h for 3 days q 21 days
Phase II
NSCLC (47 pts)
Toxicity: fatigue, nausea, dysgeusia-
3 partial responses (6%)
[102]
Quisinostat (JNJ-26481585) Mixed tumours (92 pts)
Phase I
RD 12 mg days 1,3 and 5
Toxicity: cardiovascular, fatigue, nausea
PD: increased H3Ac in hair follicles, skin and tumour.
[103]
Resminostat
RD 600 mg/day p.o. for 5 days q 14 days
Phase I
Head-and-neck refractory
Toxicity: nausea, vomiting, fatigue.
PK data, HDAC inhibition, H4Ac increase in PBMC
[69]
Romidepsin
13 mg/m2 i.v. in 4 h for days 1, 8 and 15 q 28 days
Phase II
Refractory Prostate (35 pts)
Toxicity: nausea, fatigue, vomiting and anorexia
No antitumour activity
[104]
Romidepsin
13 mg/m2 in 4 h, for days 1, 8 and 15 q 28 days
Phase II
Head and Neck (14 pts)
Toxicity: nausea, vomiting, constipation, fatigue
H3 hyperacetylation in PBMC
Reduced or stable Ki67
On microarray 641 differentially expressed genes
No consistent change ion methylation of specific genes
Upregulation of p21Waf1/Cip1.
[70]
Romidepsin
New schedule: 1–9 mg/m2 in 4 h
for days 1, 3, and 5 q 21 days
RD 7 mg/m2
Phase I
Mixed tumours (28 pts)
Increase in 3HAc in PBMC. PK data described.
Toxicity: ECG changes
[54]
SAHA
400 mg/day p.o.
Phase II
Head-and-neck, refractory (13 pts)
No response. Toxicity: anaemia, anorexia,
hyperglycemia, thrombocytopenia, dehydration
[82]
SAHA
400 mg/day p.o.
Phase II
Refractory Prostate (27 pts)
IL-6 was higher in patients with toxicity (Fatigue, nausea) [105]
SAHA
400 mg for 14 days q 21 days
Phase II
Glioblastoma (66 pts)
Analysis of tumour tissue. Increased Acetylation
of H2A, H3, H4. up-regulation of e-regulin.
PK influenced by enzyme-inducing drugs.
Toxicity: fatigue, thrombocytopenia. nausea, diarrhoea
[75]
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Table 1 Studies on epigenetic treatment alone (Continued)
SAHA
400 mg for 14 days q 21 days
Phase II
Breast (14 pts)
No antitumour activity.
Toxicity: Fatigue, nausea, diarrhoea, and lymphopenia
[106]
SAHA
400 mg for 14 days q 21 days
Phase II
Ovarian (27 pts)
No antitumour activity
Toxicity: Neutropenia, Leukopenia, Thrombocytopenia,
Constitutional, Gastrointestinal, Metabolic
[107]
SAHA
400 mg for 14 days q 21 days
Phase II
NSCLC second line (16 pts)
No antitumour activity
Toxicity: fatigue, dehydration, hyperglycemia, mild
myelosuppression
[108]
SAHA
400–800 mg for 14 days q 21 days
RD 400 mg for 14 days q 21 days
Breast, colorectal, NSCLC (16 pts) No antitumour activity. Toxicity anorexia, asthenia,
nausea, thrombocytopenia, vomiting, weight loss
[60]
SAHA
400 mg for 14 days q 21 days
Thyroid (19 pts) No antitumour activity
Toxicity: fatigue, dehydration, ataxia, pneumonia, bruises,
thrombosis, thrombocytopenia
[109]
SAHA
600 mg bid days 1–3 q 7 days or 400 mg for 14 days q 21days
Phase I
Gastrointestinal (16 pts)
DLT thrombocytopenia.
Some PK data: AUC μM/h 7.75±2.79 for 400 mg;
3.94±1.56 with 300 mg.
t ½ 1.05±0.32 – 1.49±0.82 hours
[110]
SAHA
100–500 mg once or twice daily for 14 days q 21 days
Phase I
Mixed tumours (18 pts)
MTD not reached. Recommended dose 500 for once,
200 for twice daily.
Some PK data: AUC linear with dose
[111]
SAHA
300 or 400 mg bid days 1–3 q 7 days
Mesothelioma (pretreated) (13 pts) 2 PR.
Toxicity: fatigue, anorexia, dehydration, diarrhea,
nausea, and vomiting
[112]
SAHA
2 h i.v. infusion
75–900 mg/m2/day days 1–3 q 21 days
or 300–900 mg/m2/day days 1–5 q 21 days
Phase I
Mixed tumours (37 pts)
Toxicity: myelotoxicity, fatigue, anorexia, hyperglicemia
Increase in acetylated histones in PBMC and in tumour
cells. PK data.
[113]
SAHA oral
MTD 400 mg/day or 600 mg/day days 1–3 q 7 days
Phase I
Mixed tumours (73 pts)
Toxicity: anorexia, dehydration, diarrhea, and fatigue.
In PBMC acetylation increased 2 hrs after dose,
back to basal levels at 8 hours
[114]
SAHA
300 mg tid
Breast (25 pts) Decrease of proliferation-associated genes.
No effect on methylation
[115]
SAHA
400 mg daily continuously
Melanoma (39 pts) Toxicity fatigue, nausea, lymphopenia, and hyperglycemia.
Some biochemical correlative data presented.
[116]
SAHA
300 mg tid days 1–3, 8–10, 15–17 q 21 days
Mesothelioma (pretreated) (329 pts) Randomised phase III: no benefit
Toxicity: fatigue or malaise
[117]
SB939
10–80 mg/day p. o. 3 times/week for 3 weeks q 4 weeks
RD 60 mg/day
Phase I
Mixed tumours (30 pts)
DLT: fatigue, hypokalemia, ECG alterations.
AUC proportional to dose.
HDAC increases at doses 60 mg.
[118]
SB939
10–90 mg daily five times a week q 2 wks
RD 60 mg/day
Phase I
Mixed tumours (38 pts)
PK data. No correlation of AcH3 and response.
Toxicity: fatigue, nausea, vomiting.
[83]
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Table 1 Studies on epigenetic treatment alone (Continued)
Valproate
intravenous infusion in 1 h
30-250 mg/kg/day for days 1–5 q 21 days
RD 60 mg/kg/day
Phase I
Mixed tumours (26 pts)
Toxicity: neurological.
HDAC2 decreased; H3 Acetylation increased;
VPA plasma levels 0.3-0.9 mM.
[80]
Valproate
p. o. 20-40mg/kg/day for 5 days
Phase I
Cervical cancer (12 pts)
VPA in plasma 73–170 μg/ml. (0.4-1 mM)
No correlation of H3 acetylation in tumour
biopsies and plasma VPA. Toxicity: Depressed
consciousness
[79]
Valproate
500 mg p. o. tid (target concentration 50–100 μg/ml)
(0.3-0.6 mM)
Phase II
Low-grade Neuroendocrine (8 pts)
Two tumours had a 2-4-fold increase
in Notch-1 mRNA, 3 had a decrease.
[71]
The references are included at the end of the text
5FU 5-Fluorouracil, 5mC 5-methyl Cytosine, AUC area under the curve (also a dosing calculation for Carboplatin), Bid bis in die (twice a day), DLT dose-limiting toxicity, FEC combination of Fluorouracil, Epirubicin,
Cyclophosphamide, FolFOx combination chemotherapy of Folinic acid, 5-Fluorouracil and Oxaliplatin, GI gastrointestinal, i.v. intravenously, MTD maximum tolerated dose, NSCLC non-small cell lung cancer, PBMC
peripheral blood mononuclear cells, PD pharmacodynamic, PFS progression-free survival, PK pharmacokinetics, p.o. per os (orally), PR partial response, Pt patient, q every (Latin “quaque”), RA rapid acetylator
(Hydralazyne metabolism), RD recommended dose, RR response rate, SA slow acetylator (Hydralazyne metabolism), SAHA Vorinostat, Zolinza ®, TS thymidylate Synthetase, target enzyme for 5FU activity, VPA Valproic
Acid, WBC white blood cells
(1) Oral dose of VPA titrated in each patient to obtain adequate plasma concentrations.
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Table 2 Epigenetic treatment associated with a conventional anticancer agent
Epigenetic drug Tumour type and chemo Results and data provided Reference
5-azacytidine
RD 75 mg/m2/day
days 1–4 and 15–18 q 28 days
Phase I
Erlotinib 150 mg/day
Mixed tumours (30 pts)
Aza: increasing dose (75–100) and days of
treatment (2–8)
Toxicity: rash, diarrhoea, nausea, and fatigue
[119]
5-azacytidine Ovarian cancer, platinum insensitive (30 pts) Toxicity: fatigue, myelosuppression
DR4 methylation in PBMC related to activity
[120]
5-azacytidine
75 mg/m2/day for days 1-5
Prostate cancer (22 pts)
Docetaxel (day6) , prednisone
Toxicity: myelosuppression
Reduction in GADD-45 methylation (peripheral
DNA) on day 5
Only pts that had a reduction had a response.
[61]
Abexinostat
15–45 mg tid days 1-5
Sarcoma 22 pts
Doxorubicin 75 mg/m2 day 4
Neutropenia (growth factors required), fatigue,
thrombocytopenia, and anemia.
PK of Abexinostat described. HDAC levels
inhibited in PBMC
[121]
Belinostat
1000 mg/m2/day for 5 days
Carboplatin AUC 5 day 3
Resistant ovarian cancer (29 pts)
Toxicity: neutropenia, thrombocytopenia, vomiting
No effect, study closed
[122]
Belinostat
1000 mg/m2, 48 h c.i.
Thymic epithelial (26 pts)
Cisplatin, doxorubicin, cyclophosphamide
Toxicity: nausea, diarrhea, neutropenia,
thrombocytopenia,
Immunomodulatory effect observed
[123]
Belinostat 1000 mg/m2 i.v. for days 1–3 then p.o. 2000 mg for days 4-5 Unknown primary (44 pts)
Paclitaxel, carboplatin
Randomised phase II. No clinical benefit [124]
CI-994
6 mg/m2/day for days 1–21, 28-day cycle
Phase II Pancreas.
Gemcitabine 1000 mg/m2 days 1, 8 and 15 (174 pts)
Increased incidence of neutropenia
and thrombocytopenia
No improvement of gemcitabine activity
[125]
CI-994
4–10 mg/m2/day
RD 6 mg/m2/day for days 1–14 q 21 days
Phase I
Mixed tumours (54pts)
Capecitabine 1650–2000 mg/m2/day for 14 days q 21 days
PK not altered by capecitabine.
Toxicity: Thrombocytopenia
[49]
Decitabine
45–135 mg/m2 6 h infusion for day 1
RD 90mg/m2
Phase I
Carboplatin (AUC 5 or 6) day 8
Mixed tumours (33 pts)
Dose dependent, reversible demethylation in
PBMC maximally at day 10. Demethylation of the
MAGE1A gene
Toxicity: myelosuppression
[42]
Decitabine
10 mg/m2/day for 5 days
Carboplatin AUC 5 day 8
Ovarian cancer (17 pts)
35% RR 10.2 months PFS
In PBMC and tumours global and gene-specific
demethylation.
Demethylation of MLH1, RASSF1A, HOXA10,
HOXA11 correlated with PFS
[74]
Decitabine
0.15 mg/kg i.v. daily × 5 days/wk for 2 wks
Phase I-II
Temozolomide
p.o. 75 mg/m2 daily for weeks 2–5 of a 6-week cycle
Refractory Melanoma (35 pts)
Toxicity: mainly haematological
No effect on promoters of DNA repair genes
Excellent PK and PD data (also in tumours)
[55]
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Table 2 Epigenetic treatment associated with a conventional anticancer agent (Continued)
Decitabine
days 1–5 q 28 days
10–20 mg/m2/day
Phase I
Ovarian, recurrent (10 pts)
Carboplatin AUC 5 day 5
Toxicity: myelosuppression, nausea, fatigue
global and gene-specific DNA methylation
[126]
Decitabine i.v. day 1
45 mg/m2
Carboplatin AUC 6 day 8
Ovarian cancer (15 pts)
Patients with methylated hMLH1 tumour DNA
in plasma
Decitabine appears to reduce the efficacy
of carboplatino
Decrease in global levels of methylation
with Decitabine.
[127]
Decitabine
01–0.2 mg/kg 3 days weekly
Panobinostat
10-30mg q 4 days
Temozolomide 150–200 mg/m2/day
Resistant melanoma
Toxicity: myelosuppression, fatigue, nausea
No antitumour acitivity.
[128]
Entinostat
10 mg p.o. day 1 and 15 q 28 days
Randomised phase II
NSCLC (132 pts)
Erlotinib 150 mg/day
Toxicity: rash, fatigue, diarrhoea, nausea
High E-caderin levels associated with
longer PFS
[86]
Entinostat
1–5 mg/kg days 1,8,15 q 28 days
Phase I
Mixed tumours (19pts)
13-cis retinoic acid 1 mg/kg
Toxicity: hyponatremia, neutropenia, anaemia.
PD: Increased histone acetylation
[129]
Entinostat
5 mg/week
Breast (64pts)
Examestane 25 mg/day
Randomised phase II. Patients had progressed
with AI.
Protein lysine hyperacetylation associated with
prolonged PFS
[130]
Entinostat
10 mg/2 weeks
Phase I
Mixed tumours (31 pts)
Sorafenib (400 mg tid)
Toxicity: Handfoot syndrome, nausea/vomiting,
and fatigue
[131]
Hydralazine (182 mg RA; 83 mg SA)
+ Valproate (40 mg)
Phase II (17 pts)
Mixed tumours: re-treatment of resistant patients with same
chemo as before
Toxicity: mainly haematological
Reduction in global DNA methylation, histone
deacetylase
activity, and promoter demethylation
[58]
Hydralazine
(182 mg RA; 83 mg SA)
+ Valproate (30 mg)
Phase II
Progressive Cervical cancer (36 pts)
Cisplatin + Topotecan
Advantage in PFS (10 vs. 6 months)
Molecular correlates pending.
[59]
Hydralazine
(182 mg RA; 83 mg SA)
+ Valproate (30 mg)
Phase II
Breast (16 pts)
Doxorubicin, cyclophosphamide
Decrease in 5mC content and HDAC activity.
Up- and down-regulation of many genes.
[57]
Panobinostat
alone: 20 mg for days 1,3 and 5 for 2 weeks q 3weeks
with chemo: 15 mg
Prostate (pretreated) (16 pts)
Docetaxel 75 mg/m2 q 21 days
Toxicity: dyspnea, neutropenia
Increase in histone acetylation in PBMC
No relevant antitumour actitvity
[132]
Panobinostat
30 mg/day, days 1,3 and 5 q 14 days
Recurrent glioma (12 pts)
Bevacizumab 10 mg/kg q 14 days
Toxicity: thrombocytopenia, hypophosphatemia,
hemorrhage, thrombosis.
[133]
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Table 2 Epigenetic treatment associated with a conventional anticancer agent (Continued)
Panobinostat
10 mg days 1,3 and 5 q 14 days
Phase I
Mixed tumours (12 pts)
Bevacizumab 10 mg/kg q 14 days
Everolimus 5 or 10 mg
Toxicity: Mucositis, arrhythmia.
No consistent change in HDAC activity in PBMC
[134]
Panobinostat
30 mg days 1 and 4
NSCLC, HNC
Erlotinib 100 mg/day
DLT: cardiac, nausea. Fatigue.
PK and PD data.
[135]
Panobinostat
20 mg
Gleevec-resistant GIST (12 pts) No actibvity but evidence of 3HAc increase
in PBMC
[136]
Panobinostat 10 mg days 1, 3 and 5 Paclitaxel, Carbopaltin AUC=5
Phase I
Miscellaneous tumours (12 pts)
Toxicity: diarrhea, fatigue, and vomiting [137]
SAHA
100-400mg/day
RD 300 mg
GI carcinoma (14 pts)
Radiotherapy
30 Gy in 3 Gy/day over 2 weeks
Toxicity: fatigue
Diarrhoea proportional to the volume of
intestine irradiated.
[41, 138]
SAHA
200–800 mg/day 1week q 2 weeks
RD 600 mg/day
Refractory colorectal
FolFOx (21 pts)
Toxicity: fatigue, anorexia, dehydration
no consistent modulation of TS expression
[88]
SAHA
days 1–3 q 14 days 600–2000 mg/day
RD 1700 mg once 600 mg tid
Phase I
Refractory colorectal (43 pts)
FU-LV
toxicity: neutropenia, thrombocytopenia, fatigue,
nausea or vomiting, anorexia, mucositis.
No consistent effect on biopsies.
[139]
SAHA
400 mg/day
Tamoxifen (43 pts)
Hormone-resistant breast
Histone hyperacetylation and higher baseline
HDAC2 levels that correlated with response
[84]
SAHA
RD 400 mg/day 14 days q 21 days
600 mg/day bid q 21days
Phase I (28 pts)
Mixed tumours
Paclitaxel (200 mg/m2) (Carboplatin (AUC 6)
Toxicity: emesis, neutropaenia, fatigue [140]
SAHA
400 mg/day
Randomised Phase II
vs. placebo
NSCLC 94 pts
Paclitaxel Carboplatin
Toxicity thrombocytopenia, nausea, emesis, fatigue.
RR 34% vs. 12%
[85]
SAHA
400 mg/day
Phase I-II
resistant colorectal
5FU-leucovorin
Failed to establish an MTD
Toxicity: fatigue, thrombocytopenia and mucositis.
Intratumoral TS downregulation in one patient.
Acetylation of H3 in PBMCs
[141]
SAHA
200–300 mg bid days 1–3 q 7 days
Phase I-II
Breast (54 untreated pts)
Paclitaxel 90 mg/m2/week Bevacizumab 10 mg/kg
Increased diarrhoea with the addition of SAHA
Increased acetylation of Hsp90 and α-tubulin
[66]
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Table 2 Epigenetic treatment associated with a conventional anticancer agent (Continued)
SAHA
400 mg/day 14 days
Phase II
Glioblastoma (37 pts)
Bortezomib 1.3 mg/m2/day days 1,4,8 and 11 q 21days
Toxicity: Fatigue.
No therapeutic advantage
[142]
SAHA
100–200 mg/day for days 1–14 q 21 days
Phase I
Mixed tumours
12 patients
Docetaxel 50–75 mg/m2 day 4 q 21 days
Excessive toxicity: neutropenic fever,
cardiac, bleeding
No PK interaction
[143]
SAHA + VPA
for days 1–2 400–100 mg/day
RD 800 mg/day
Phase I (32 pts)
Mixed tumours
Doxorubicin on day 3
20 mg/m2 weekly
Toxicity: fatigue, nausea
HDAC2 expression in PBMC similar to tumours
no correlation of SAHA levels with acetylation
[144]
SAHA
300 mg/day for 16 days q 28 days
Phase I
Mixed tumours (22pts)
Marizomib
0.15-0.7 mg/m2 i.v.
days 1, 8 and 15 q 28 days
Toxicity: Fatigue, nausea, diarrhea, vomiting,
PK data. Data on proteasome inhibition in PBMC
[76]
SAHA
300 mg for days 1–3 q 8 days
Bortezomib
1.3 mg/m2 days1,8 and 15 q 21 days
NSCLC (21 pts)
Preoperative treatment.
Toxicity: fatigue and hypophosphatemia
[145]
SAHA
200–300 mg tid for days 1–4 and 8-11
Bortezomib 1–1.3 mg/m2 for day 9
Phase I (60 pts)
Comparison in PBMC and biopsies after SAHA and
SAHA-Bort. Dcreased Nur77 expression.
[146]
SAHA
400 mg p.o.
for days 1–7 and 15–21 q 28 days
NSCLC (33 pts) Erlotinib-resistant
Erlotinib 150 mg/day
No clinical activity
Toxicity: anemia, fatigue and diarrhoea.
[147]
SAHA
300–400 mg/day for days 1-14
Gastric (30 pts)
Capecitabine, Cisplatin
Toxicity: thrombocytopenia, fatigue, stomatitis,
anorexia
H3Ac correlated with SAHA dose
[148]
SAHA
200–400 mg p.o. for days 1–14 q 21 days
Mixed tumours (35 pts)
Sorafenib 400 mg p.o. bid
Recommended dose for SAHA 300 mg/die, but not
tolerated.
Toxicity: hand-foot syndrome. No tumour response.
[149]
SAHA
tid for days 1–4 and 8–11 q 21 days
Mixed tumours (29 pts)
Bortezomib 1.3 mg/m2 i.v. for days 1, 4, 8 and 11
Toxicity thrombocytopenia, fatigue, increased ALT,
elevated INR, and diarrhea.
PK data provided.
[150]
SAHA
p.o. for days 1–14
MTD 400 mg
Mixed tumours (23 pts)
Bortezomib i.v. for days 1, 4, 8 and 11 q 21 days.
MTD 1.3 mg/m2
Toxicity: fatigue, hyponatremia, nausea, anorexia
Some PK data
[151]
SAHA
300 mg daily
Mixed tumours (78 pts)
Pazopanib 600 mg daily
Toxicity: thrombocytopenia, neutropenia, fatigue,
hypertension, diarrhea, vomiting
[152]
N
erviet
al.ClinicalEpigenetics
 (2015) 7:127 
Page
12
of
20
Table 2 Epigenetic treatment associated with a conventional anticancer agent (Continued)
SAHA 400 mg daily Gefitinib 250 mg
NSCLC pretreated (52 pts)
No clinical benefit
Toxicity: anorexia, diarrhea, fatigue, anemia
[153]
Valproate
30–90 mg/kg/day
for days 1–5 q 21 days
MTD 75 mg/kg/day
Karenitecin i.v. 0.8-1 mg/m2/day
for days 3–7 q 21 days
Melanoma: xenografts
Phase I-II (39 pts)
Toxicity: somnolence, fatigue
VPA levels at MTD 1.28 mMol
Histone hyperacetylation was observed in PBMC. No
effect of valproate on Karenitecin PK
[154]
Valproate
15–160 mg/kg/day for days 1–3
RD 120 mg/kg/day
Phase I (44 pts)
Mostly breast
FEC day 3
Toxicity: somnolence, myelosuppression
Histone acetylation in tumour samples and in
PBMCs correlated with valproic acid levels and
was further linked to baseline HDAC2 but not to
HDAC6 expression
[43]
Valproate
10–90 mg/kg/day
Melanoma (32 pts)
Dacarbazine 800 mg/m2 q 21 days,
interferon-α 600.000 IU twice daily
Toxicity: neurological, myelosuppression
Acetylation in PBMC measured.
“casting some doubts on the clinical use of VPA in
this setting”.
[155]
Valproate
Dose escalated to obtain active plasma concentration
Mesothelioma resistant to cisplatin (45 pts)
Doxorubicin 60 mg/m2 q 21 days
Toxicity: myelosuppression
16% partial response rate
[156]
Valproate
15–160 mg/kg/day for days 1–3
MTD 140
Phase I
Mixed tumours (48pts)
Epirubicin 100 mg/m2 for day 3
Toxicity: somnolence, confusion, neutropenia
VPA levels correlate with acetylation in PBMC
Plasma VPA higher than in vitro effective
concentrations
[44]
References are included at the end of the text
A.I. aromatase inhibitor, 5FU 5-Fluorouracil, 5mC 5-methyl Cytosine, AUC area under the curve (also a dosing calculation for Carboplatin), Bid bis in die (twice a day), DLT dose-limiting toxicity, FEC combination of
Fluorouracil, Epirubicin, Cyclophosphamide, FolFOx combination chemotherapy of Folinic acid, 5-Fluorouracil and Oxaliplatin, GI gastrointestinal, GIST gastrointestinal stromal tumour, HNC head-and-neck carcinoma, i.v.
intravenously, MTD maximum tolerated dose, NSCLC non-small cell lung cancer, PBMC peripheral blood mononuclear cells, PD pharmacodynamic, PFS progression-free survival, PK pharmacokinetics, p.o. per os (orally),
PR partial response, Pt patient, q every (Latin “quaque”), RA rapid acetylator (Hydralazyne metabolism), RD recommended dose, RR response rate, SA slow acetylator (Hydralazyne metabolism), SAHA Vorinostat, Zolinza
®, TS Thymidylate Synthetase, target enzyme for 5FU activity, VPA Valproic Acid, WBC white blood cells
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This also happens for HDAC inhibitors that include old
molecules (such as valproic acid (VPA) [52] and a dozen
compounds that have been recently synthesised [53].
Pharmacokinetics
To obtain an authentic effect on epigenetic mechanisms,
the choice of the dose and schedule of administration is
crucial since, especially for demethylating agents, if the
drug concentration is too high this may result in cell
toxicity or in a “traditional” antiproliferative effect. Fur-
thermore, when a combination is used, the epigenetic
effect must persist during chemotherapy (and possibly
also later) in order to obtain an adequate synergism. This
concept is guiding recent studies on new schedules of
drug administration, as is the case for romidepsin [54].
Detailed data on pharmacokinetics have been published
for several drugs (see Tables 1 and 2 for a complete list).
The pharmacology of demethylating agents has been ori-
ginally described in the past, and recent analyses mostly
concern their interaction with other agents used in com-
bination, such as temozolomide [55].
The pharmacology of HDAC inhibitors is particularly
complex since many of these compounds act as enzyme
inducers and may therefore modify their own kinetics
when repeated dosing is used, or the pharmacology of
associated drugs.
Drug concentrations in plasma are generally low, and
a very sensitive assay, such as HPLC coupled to mass
spectrometry, is required to obtain reliable data [56].
Individual characteristics may influence the kinetic
parameters (pharmacogenetics): in the case of hydralazine,
fast or slow metabolism is genetically determined, and in
some studies, doses have been escalated or de-escalated
according to individual metabolic parameters [57–59].
Pharmacodynamic effect
The most interesting part of the evaluation of anticancer
drugs, particularly when dealing with an innovative
mechanism of action, is the study of their effect in
tumour cells. Several technical problems arise when trying
to quantify the effect of epigenetic drugs, especially in
solid tumours: it is difficult to decide what to measure,
when and where.
Concerning demethylating agents, the effect is gener-
ally measured by evaluating global DNA methylation,
but some authors determined the methylation status of
specific genes that had previously been selected [60–62]
and the level of expression of foetal haemoglobin has
also been used as a PD marker [63]. The subject of DNA
methylation may also be related to drug resistance
caused by the activity of O(6)-methylguanine DNA
methyltransferase (MGMT) that has been described in
cerebral tumours [3, 64]. Decitabine has been used in an
attempt to reduce methylation of genes involved in DNA
repair in melanoma patients treated with temozolomide
[55] but no such effect was evident even if decitabine
caused hypomethylation of the HbF gene promoter.
The situation is more complex for HDAC inhibitors
since not all drugs inhibit the different enzyme classes
that are present in eukaryotic cells to the same extent.
Some molecules have a wide inhibiting effect [65]; some
are more restricted, and class-specific inhibitors such as
CHR-3996, specific for class I HDACs enzymes [45], are
being introduced in the clinics. Furthermore, the inhib-
ition of de-acetylating enzymes may result in acetylation
not only of histones, but also of other proteins, such as
tubulin and Hsp90 that are involved in anticancer drug ac-
tivity/resistance or in unrelated cellular pathways [66, 67].
An additional difficulty derives from the definition of a
cut-off value: some authors, for example, required a
doubling of histone acetylation to consider a result as
“relevant” [68] but this was not mandatory in many
other studies.
The effect of HDAC inhibitors was generally determined
in terms of enzymatic activity, but in some cases histone
acetylation, particularly H3 and H4, has been used as
marker of activity. A consistent increase of H3 acetylation
in peripheral blood mononuclear cells (PBMC) at effective
doses has been observed with several agents, even if large
inter-patient variations were often reported [69], and,
more importantly, intratumoral H3 acetylation increase
did not always correlate with response [70].
The effect of epigenetic treatment has also been evalu-
ated by looking at specific genes in terms of expression
[57, 62] or re-activation [71]. It is becoming clear that
many elements are involved, and that it may be difficult to
identify a consistent pattern in gene activation-inactivation
[72] to be used as a marker of epigenetic activity.
The gold standard of pharmacodynamic studies is the
evaluation of the effects in tumours. The study of malig-
nant cells is certainly more complicated in patients with
solid tumours than in leukaemia since cancer cells are
more difficult to obtain, especially at multiple time points.
Some reports on the evaluation of epigenetic therapy in
solid tumour tissues have been published and deserve spe-
cial consideration. The number of evaluable samples was
often low, but informative results were obtained and
reported [41, 73]. In ovarian cancer, it has been possible to
evaluate the activity of demethylating agents on cells
obtained from ascitic fluid and a gene-specific reduction
of DNA methylation was evident [74]. Serial biopsies were
obtained from patients with in head-and-neck carcinomas
[70], glioblastoma [75], cervical and breast cancer and
other tumours [57, 58, 66].
To overcome the difficulty in obtaining tumour sam-
ples, several groups have focused on the identification of
surrogate markers. PBMC represent the most commonly
used alternative. It is possible to measure HDAC activity
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and histone acetylation or DNA methylation. PBMC
have also been used, in studies of drug combinations, to
measure the target of non-epigenetic drug [76]. When
PBMC and tumour biopsies were compared, however,
results were not always consistent [66]. PBMC represent a
“surrogate” tissue, and further improvement is required in
order to make results obtained in these cells more repre-
sentative of what is actually taking place in cancer.
A promising technique is the evaluation of circulating
cell-free DNA [77] on which several specific analyses to
identify epigenetic modifications can be performed [78].
The activity of demethylating agents has been evaluated
by measuring the methylation status of circulating cell-
free DNA in plasma in patients with refractory advanced
non-small cell lung cancer (NSCLC) [62]. This is an in-
teresting alternative with applications in many aspects of
medicine, but further studies are required before it can
be considered a reliable marker of epigenetic activity.
To obtain an adequate effect, sufficient drug concen-
trations must persist in the target cells for an adequate
time. If there is a relationship between plasma kinetics
and tissue effect (PK/PD relationship), drug dosing may
be adapted on the basis of PK parameters that are easier
to obtain. The permanence of a sufficient drug concen-
tration or of a measurable effect has been evaluated in
different tumour types and provides a rationale for the
antitumour activity observed (see Tables 1 and 2 for
details). Concerning the PK/PD relationship, data are diffi-
cult to interpret: no correspondence was found between
plasma levels of valproate and histone acetylation in cer-
vical cancer [79] so that PD assays may be required until
we can devise more efficient PK models.
Toxic side effects
One of the most interesting characteristics of many epi-
genetic drugs is that toxicity, at doses sufficient to achieve
effective plasma concentrations, is generally very mild and
has been described in detail in many studies of epigenetic
agents used alone or in combination with standard anti-
cancer agents (see Tables 1 and 2 for details).
Toxicity of demethylating agents
The best known agents that interfere with DNA methyla-
tion are decitabine and 5-azacytidine. More limited data
are available for zebularine [46]. Since these agents also
have traditional antiproliferative activity, the dose used
plays a key role. At high doses, 5-azacytidine can cause
neutropenia [68], similar to what is described for trad-
itional anticancer drugs. It is generally assumed that in
order to exploit the epigenetic action, it is necessary to
use very low doses that are insufficient to cause any anti-
proliferative effect.
Toxicity of HDAC inhibitors
VPA is the best known molecule in this class since it has
been used for many years as an antiepileptic drug: it is
extremely well tolerated by patients, and also its long-term
effects are well known. The most commonly reported
complaints are neurological symptoms (such as dizziness)
that are generally transitory and reversible [79, 80]. Neuro-
logical symptoms may become excessive when VPA is
combined with other agents [63].
When vorinostat (SAHA) was tested in mice, relevant
systemic toxicity was observed only at high doses [81].
In patients, anaemia, anorexia, hyperglycaemia, thrombo
cytopenia, fatigue and nausea have frequently been re-
ported [82]. Similar toxic side effects were described for
SB939 [83], for rosminostat [69] and romidepsin [70].
ECG abnormalities of different severity are the most
concerning toxic side effects of CHR3996 [45] and of
romidepsin [54].
Antitumour activity
In a phase III trial of chemotherapy ± epigenetic treatment
in cancer of the uterine cervix [59], there was an increase
in progression-free survival, and the analysis of molecular
correlates is pending.
Concerning phase II studies, that evaluated the antitu-
mour activity of epigenetic agents alone or in combination
with standard anticancer treatment, several studies have
been reported. In many cases, results were described in
terms of reduction of tumour volume in advanced disease
resistant to several lines of anticancer treatments, similarly
to what is standard for the evaluation of traditional anti-
proliferative agents [74, 82, 84, 85]. It is probably not sur-
prising that several trials were reported as negative (see
Tables 1 and 2 for details). Responses were evaluated
according to Response Evaluation Criteria In Solid Tumors
(RECIST): these may be useful for conventional anticancer
therapies but do not seem adequate for epigenetic treat-
ments that may result in disease stabilisation rather than in
tumour shrinkage.
The evaluation of an epigenetic treatment, which is
strictly connected to gene expression, can be performed
more accurately in diseases where the genetic influence
on the activity of the antitumour treatment is known.
For this reason, the choice to evaluate the combination
of entinostat and erlotinib in NSCLC was very sound
[86]. The addition of the epigenetic agent, however, only
improved progression-free survival (PFS) in tumours
with high levels of e-cadherin, suggesting that this may
represent a selection criterion for further studies.
The neo-adjuvant treatment of breast cancer represents
a unique possibility in order to evaluate the activity of new
agents. Not only new anticancer agents but also epigenetic
therapy (hydralazine and valproate) have been tested in
this setting [57], and the analysis of tumour biopsies
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confirmed that an epigenetic effect in terms of demethyla-
tion and of histone acetylation was detectable.
An interesting tactic was to evaluate the addition of
epigenetic treatment in order to prevent or to reverse
resistance due to the overexpression of a specific gene.
This is the case, for example, of the increase in thymidylate
synthase induced by fluorouracil treatment [87]. A clinical
trial performed to demonstrate that this can be obtained in
patients proved that treatment was feasible even if no clin-
ically meaningful effect was obtained and no data were
available for PD evaluation [88]. In a different study,
patients with tumours progressing during standard chemo-
therapy were treated with the same regimen with the
addition of hydralazine and valproate [58]. Data were
analysed in detail, and even if tumour response was
limited, there was evidence that adequate plasma con-
centrations were achieved and that an epigenetic effect
was present. A similar approach was used in melanoma
patients treated with temozolomide and decitabine:
there was no antitumour activity even in the presence
of a measurable PD effect [55].
Conclusions
Epigenetic therapy is being more and more recognised as
an effective and well-tolerated treatment of cancer. Data in
leukaemias and myelodysplastic syndromes are now con-
sistent, and the success obtained in cutaneous lymphomas
represents a proof of principle that solid tumours may also
respond. This is also supported by preclinical data; still
clinical results fall short of expectations: several reasons
may explain this discrepancy.
We are convinced that, similarly to what has been ob-
served for tyrosine-kinase inhibitors in cancer [89], we
need a better selection of tumours and of patients that
may benefit from these treatments. It has already been
stated that epigenetic drugs, and HDAC inhibitors in par-
ticular, “might be useful only in those tumours in which
HDACs are directly involved in the pathogenesis” [27].
It is not surprising that clinical results have generally
been disappointing: standard evaluation of anticancer
activity, mostly based on tumour volume reduction, may
not be an adequate index of activity for epigenetic treat-
ment. Epigenetics is a complex mechanism of gene regu-
lation: it will take time before we can exploit it at its
best. We definitely need more appropriate tests to select
potentially responding tumours, but we also need agents
with demonstrated epigenetic activity and solid data in
order to choose the most effective dose and schedule.
Several technical issues remain to be solved and this
will keep researchers busy, both in preclinical and clinical
settings, for a long time.
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